Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,799.40 | 29.30 | -0.33% |
CAC 40 | 7,766.71 | 43.24 | 0.56% |
DAX 40 | 24,206.91 | 133.24 | 0.55% |
Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
FTSE 100 | 8,854.18 | 47.65 | 0.54% |
HKSE | 24,148.07 | 260.24 | 1.09% |
NASDAQ | 20,418.46 | 5.95 | 0.03% |
Nikkei 225 | 39,633.83 | 54.98 | -0.14% |
NZX 50 Index | 12,732.84 | 126.18 | -0.98% |
S&P 500 | 6,225.52 | 4.46 | -0.07% |
S&P/ASX 200 | 8,562.60 | 28.10 | -0.33% |
SSE Composite Index | 3,496.97 | 0.51 | -0.01% |